Evidence map›Paper›PMID 34668451›Full record

ArticleLeukemia & lymphoma2022

Value of measurable residual disease monitoring in patients with acute promyelocytic leukemia in the era of frontline 'chemotherapy-free' therapy.

Jorge M Ramos Perez, Keyur P Patel, Sanam Loghavi, Guillermo Garcia-Manero, Gautam Borthakur, Elias Jabbour, William Wierda, Sherry Pierce, Mark Brandt, Steven Kornblau and 14 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Leukemia & lymphoma, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.4field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 10 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Review
  5. Outcome of Patients With Relapsed Acute Promyelocytic Leukemia.Clinical lymphoma, myeloma & leukemia · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors at 1 institution in 1 country.

Jorge M Ramos PerezLeukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Keyur P PatelHematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States.
Sanam LoghaviHematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States.
Guillermo Garcia-ManeroLeukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Gautam BorthakurLeukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID 0000-0001-7679-6453
Elias JabbourLeukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
William WierdaLeukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Sherry PierceLeukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Mark BrandtLeukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Steven KornblauLeukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Tapan KadiaLeukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Naval DaverLeukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Courtney D DiNardoLeukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Nitin JainLeukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Musa YilmazLeukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Nicholas ShortLeukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Srdan VerstovsekLeukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID 0000-0002-6912-8569
Alessandra FerrajoliLeukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Michael AndreeffLeukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Marina KonoplevaLeukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Daniel RiveraLeukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
David McCueLeukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Hagop M KantarjianLeukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Farhad RavandiLeukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID 0000-0002-7621-377X
The University of Texas MD Anderson Cancer Center · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8M
NCI NIH HHS P30 CA016672
6 · The paper itself

Abstract

Acute promyelocytic leukemia (APL) is characterized by the chromosomal translocation

Indexed as

ArsenicalsLeukemia, Promyelocytic, AcuteArsenic TrioxideHumansNeoplasm, ResidualOxidesRecurrenceTranslocation, GeneticTretinoinArsenicalsArsenic TrioxideOxidesTretinoinAPLATRA plus ATOMRD monitoring

Identifiers

PMID34668451
PMCPMC11749422
OpenAlexW3205067818

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.